Pralsetinib, another kinase inhibitor, can inhibit RET fusions and mutations [159] and has been indicated for the treatment of RET-mutant MTC as well as RET fusion-positive thyroid carcinoma [160]. This evidence concerns the gene RET and medullary thyroid gland carcinoma.